Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Christopher T. Giordano | CEO, President & Director | 644.77k | -- | 1975 |
| Dr. Stuart Rich M.D. | Chief Medical Officer & Director | 481.22k | -- | 1950 |
| Mr. Thomas A. McGauley | Interim CFO and Principal Financial Officer & Principal Accounting Officer | -- | -- | 1973 |
| Mr. Doug Randall | Chief Business Officer | -- | -- | -- |
| Dr. Douglas Hay | Senior Vice President of Regulatory Affairs | -- | -- | -- |
Tenax Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 4
Description
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Corporate Governance
Upcoming Events
May 12, 2025 at 12:30 PM UTC - May 16, 2025 at 12:30 PM UTC
Tenax Therapeutics, Inc. Earnings Date
Recent Events
September 10, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission